View Item 

Show simple item record

Systematic review with network meta‐analysis: pharmacological prophylaxis against post‐ ERCP pancreatitis

dc.contributor.authorAkshintala, V. S.en_US
dc.contributor.authorHutfless, S. M.en_US
dc.contributor.authorColantuoni, E.en_US
dc.contributor.authorKim, K. J.en_US
dc.contributor.authorKhashab, M. A.en_US
dc.contributor.authorLi, T.en_US
dc.contributor.authorElmunzer, B. J.en_US
dc.contributor.authorPuhan, M. A.en_US
dc.contributor.authorSinha, A.en_US
dc.contributor.authorKamal, A.en_US
dc.contributor.authorLennon, A. M.en_US
dc.contributor.authorOkolo, P. I.en_US
dc.contributor.authorPalakurthy, M. K.en_US
dc.contributor.authorKalloo, A. N.en_US
dc.contributor.authorSingh, V. K.en_US
dc.date.accessioned2013-12-04T18:57:03Z
dc.date.available2015-01-05T13:54:43Zen_US
dc.date.issued2013-12en_US
dc.identifier.citationAkshintala, V. S.; Hutfless, S. M.; Colantuoni, E.; Kim, K. J.; Khashab, M. A.; Li, T.; Elmunzer, B. J.; Puhan, M. A.; Sinha, A.; Kamal, A.; Lennon, A. M.; Okolo, P. I.; Palakurthy, M. K.; Kalloo, A. N.; Singh, V. K. (2013). "Systematic review with network meta‐analysis: pharmacological prophylaxis against post‐ ERCP pancreatitis." Alimentary Pharmacology & Therapeutics 38(11-12): 1325-1337.en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/101786
dc.publisherJohn Wiley & Sonsen_US
dc.titleSystematic review with network meta‐analysis: pharmacological prophylaxis against post‐ ERCP pancreatitisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/101786/1/apt12534-sup-0002-AppendixS2.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/101786/2/apt12534-sup-0001-AppendixS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/101786/3/apt12534.pdf
dc.identifier.doi10.1111/apt.12534en_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceGuelrud M, Mendoza S, Viera L, Gelrud D. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 1990; 36: 44 – 7.en_US
dc.identifier.citedreferenceYoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post‐endoscopic retrograde cholangiopancreatography pancreatitis in high‐risk patients: a prospective, randomized, placebo‐controlled trial. Pancreas 2008; 37: 366 – 70.en_US
dc.identifier.citedreferenceMori S, Itoh Y, Shinohata R, et al. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003; 92: 420 – 3.en_US
dc.identifier.citedreferenceKeck T. Site‐specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis. Pancreatology 2001; 1: 656 – 61.en_US
dc.identifier.citedreferenceBinmoeller KF, Dumas R, Harris AG, et al. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992; 37: 773 – 7.en_US
dc.identifier.citedreferenceWu SD, Zhang ZH, Jin JZ, et al. Effects of different drugs on the sphincter of Oddi motility: study with choledochoscope manometry. Zhonghua yi xue za zhi 2005; 85: 1911 – 5.en_US
dc.identifier.citedreferenceDi Francesco V, Angelini G, Zoico E, et al. Effect of native somatostatin on sphincter of Oddi motility in patients with acute recurrent pancreatitis. A pilot study with ultrasound‐secretin test. Dig Liver Dis 2006; 38: 268 – 71.en_US
dc.identifier.citedreferenceXu LH, Qian JB, Gu LG, et al. Prevention of post‐endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla. J Gastroenterol Hepatol 2011; 26: 1139 – 44.en_US
dc.identifier.citedreferenceMatsushita M, Takakuwa H, Shimeno N, et al. Epinephrine sprayed on the papilla for prevention of post‐ERCP pancreatitis. J Gastroenterol 2009; 44: 71 – 5.en_US
dc.identifier.citedreferencePezzilli R, Romboli E, Campana D, et al. Mechanisms involved in the onset of post‐ERCP pancreatitis. JOP 2002; 3: 162 – 8.en_US
dc.identifier.citedreferenceAkashi R, Kiyozumi T, Tanaka T, et al. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc 2002; 55: 50 – 4.en_US
dc.identifier.citedreferenceFreeman ML, Guda NM. Prevention of post‐ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59: 845 – 64.en_US
dc.identifier.citedreferenceElta GH, Barnett JL, Wille RT, et al. Pure cut electrocautery current for sphincterotomy causes less post‐procedure pancreatitis than blended current. Gastrointest Endosc 1998; 47: 149 – 53.en_US
dc.identifier.citedreferenceStefanidis G, Karamanolis G, Viazis N, et al. A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis. Gastrointest Endosc 2003; 57: 192 – 7.en_US
dc.identifier.citedreferenceVerma D, Kapadia A, Adler DG. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta‐analysis of adverse outcomes. Gastrointest Endosc 2007; 66: 283 – 90.en_US
dc.identifier.citedreferenceBuscaglia JM, Simons BW, Prosser BJ, et al. Severity of post‐ERCP pancreatitis directly proportional to the invasiveness of endoscopic intervention: a pilot study in a canine model. Endoscopy 2008; 40: 506 – 12.en_US
dc.identifier.citedreferenceOhno T, Katori M, Nishiyama K, et al. Direct observation of microcirculation of the basal region of rat gastric mucosa. J Gastroenterol 1995; 30: 557 – 64.en_US
dc.identifier.citedreferenceIgawa M, Miyaoka M, Saitoh T. Influence of topical epinephrine application on microcirculatory disturbance in subjects with ulcerative colitis evaluated by laser doppler flowmetry and transmission electron microscopy. Dig Endosc 2000; 12: 126 – 30.en_US
dc.identifier.citedreferenceNakahata N, Nakanishi H, Suzuki T. Depressive effect of epinephrine mediated via adrenergic beta‐receptor in isolated rat colon and duodenum. Jpn J Pharmacol 1977; 27: 341 – 9.en_US
dc.identifier.citedreferenceSarles JC, Awad R. Role of the autonomic nervous system in the rabbit sphincter of Oddi. Surg Gastroenterol 1984; 3: 41 – 6.en_US
dc.identifier.citedreferenceAlvan G, Orme M, Bertilsson L, et al. Pharmacokinetics of indomethacin. Clin Pharmacol Ther 1975; 18: 364 – 73.en_US
dc.identifier.citedreferenceHelleberg L. Clinical pharmacokinetics of indomethacin. Clinical Pharmacokinet 1981; 6: 245 – 58.en_US
dc.identifier.citedreferenceMazaki T, Mado K, Masuda H, et al. Prophylactic pancreatic stent placement and post‐ERCP pancreatitis: an updated meta‐analysis. J Gastroenterol 2013; PMID: 23612857 [Epub ahead of print].en_US
dc.identifier.citedreferenceHarewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc 2005; 62: 367 – 70.en_US
dc.identifier.citedreferenceKawaguchi Y, Ogawa M, Omata F, et al. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography. World J Gastroenterol 2012; 18: 1635 – 41.en_US
dc.identifier.citedreferenceSpellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013; 368: 299 – 302.en_US
dc.identifier.citedreferenceMedicare Part B Drug Average Sales Price. Volume 2012. Centers for Medicare & Medicaid Services. Available at: http://www.cms.gov/Medicare/Medicare.html. Accessed September 15, 2012.en_US
dc.identifier.citedreferenceDas A, Singh P, Sivak MV Jr, et al. Pancreatic‐stent placement for prevention of post‐ERCP pancreatitis: a cost‐effectiveness analysis. Gastrointest Endosc 2007; 65: 960 – 8.en_US
dc.identifier.citedreferenceElmunzer BJ, Higgins PD, Saini SD, et al. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high‐risk ERCP? Post hoc efficacy and cost‐benefit analyses using prospective clinical trial data. Am J Gastroenterol 2013; 108: 410 – 5.en_US
dc.identifier.citedreferenceFreeman ML, DiSario JA, Nelson DB, et al. Risk factors for post‐ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425 – 34.en_US
dc.identifier.citedreferenceCheng CL, Sherman S, Watkins JL, et al. Risk factors for post‐ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101: 139 – 47.en_US
dc.identifier.citedreferenceWang P, Li ZS, Liu F, et al. Risk factors for ERCP‐related complications: a prospective multicenter study. Am J Gastroenterol 2009; 104: 31 – 40.en_US
dc.identifier.citedreferenceZhou W, Li Y, Zhang Q, et al. Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis: a retrospective analysis of 7,168 cases. Pancreatology 2011; 11: 399 – 405.en_US
dc.identifier.citedreferenceBrust R, Thomson AB, Wensel RH, et al. Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol. Gastrointest Endosc 1977; 24: 77 – 9.en_US
dc.identifier.citedreferenceOdes HS, Novis BN, Barbezat GO, et al. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion 1977; 16: 180 – 4.en_US
dc.identifier.citedreferenceArata S, Takada T, Hirata K, et al. Post‐ERCP pancreatitis. J Hepatobiliary Pancreat Sci 2010; 17: 70 – 8.en_US
dc.identifier.citedreferenceAnderson MA, Fisher L, Jain R, et al. Complications of ERCP. Gastrointest Endosc 2012; 75: 467 – 73.en_US
dc.identifier.citedreferenceDumonceau JM, Andriulli A, Deviere J, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post‐ERCP pancreatitis. Endoscopy 2010; 42: 503 – 15.en_US
dc.identifier.citedreferenceElmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post‐ERCP pancreatitis. N Engl J Med 2012; 366: 1414 – 2211.en_US
dc.identifier.citedreferenceAdes AE. ISPOR states its position on network meta‐analysis. Value Health 2011; 14: 414 – 6.en_US
dc.identifier.citedreferenceLi T, Puhan MA, Vedula SS, et al. Network meta‐analysis‐highly attractive but more methodological research is needed. BMC Med 2011; 9: 79.en_US
dc.identifier.citedreferenceLefebvre C, Manheimer E, Glanville J. Chapter 6: searching for studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at: http://www.cochrane.org/training/cochrane-handbook. Accessed January 18, 2012.en_US
dc.identifier.citedreferenceElmunzer BJ, Waljee AK, Elta GH, et al. A meta‐analysis of rectal NSAIDs in the prevention of post‐ERCP pancreatitis. Gut 2008; 57: 1262 – 7.en_US
dc.identifier.citedreferenceDai HF, Wang XW, Zhao K. Role of nonsteroidal anti‐inflammatory drugs in the prevention of post‐ERCP pancreatitis: a meta‐analysis. Hepatobiliary Pancreat Dis Int 2009; 8: 11 – 6.en_US
dc.identifier.citedreferenceZheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post‐ERCP pancreatitis: a complementary meta‐analysis. Gut 2008; 57: 1632 – 3.en_US
dc.identifier.citedreferenceOmata F, Deshpande G, Tokuda Y, et al. Meta‐analysis: somatostatin or its long‐acting analogue, octreotide, for prophylaxis against post‐ERCP pancreatitis. J Gastroenterol 2010; 45: 885 – 95.en_US
dc.identifier.citedreferenceAndriulli A, Caruso N, Quitadamo M, et al. Antisecretory vs. antiproteasic drugs in the prevention of post‐ERCP pancreatitis: the evidence‐based medicine derived from a meta‐analysis study. JOP 2003; 4: 41 – 8.en_US
dc.identifier.citedreferenceChen B, Fan T, Wang CH. A meta‐analysis for the effect of prophylactic GTN on the incidence of post‐ERCP pancreatitis and on the successful rate of cannulation of bile ducts. BMC Gastroenterol 2010; 10: 85.en_US
dc.identifier.citedreferenceShao LM, Chen QY, Chen MY, et al. Nitroglycerin in the prevention of post‐ERCP pancreatitis: a meta‐analysis. Dig Dis Sci 2010; 55: 1 – 7.en_US
dc.identifier.citedreferenceBang UC, Nojgaard C, Andersen PK, et al. Meta‐analysis: nitroglycerin for prevention of post‐ERCP pancreatitis. Aliment Pharmacol Ther 2009; 29: 1078 – 85.en_US
dc.identifier.citedreferenceBai Y, Xu C, Yang X, et al. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta‐analysis of randomized, double‐blind, placebo‐controlled trials. Endoscopy 2009; 41: 690 – 5.en_US
dc.identifier.citedreferenceLi S, Cao G, Chen X, et al. Low‐dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta‐analysis. Eur J Gastroenterol Hepatol 2012; 24: 477 – 81.en_US
dc.identifier.citedreferenceChen S, Shi H, Zou X, et al. Role of ulinastatin in preventing post‐endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp? Pancreas 2010; 39: 1231 – 7.en_US
dc.identifier.citedreferenceZheng M, Chen Y, Bai J, et al. Meta‐analysis of prophylactic allopurinol use in post‐endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008; 37: 247 – 53.en_US
dc.identifier.citedreferenceBai Y, Gao J, Zhang W, et al. Meta‐analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008; 28: 557 – 64.en_US
dc.identifier.citedreferenceZheng M, Bai J, Yuan B, et al. Meta‐analysis of prophylactic corticosteroid use in post‐ERCP pancreatitis. BMC Gastroenterol 2008; 8: 6.en_US
dc.identifier.citedreferenceBai Y, Gao J, Shi X, et al. Prophylactic corticosteroids do not prevent post‐ERCP pancreatitis: a meta‐analysis of randomized controlled trials. Pancreatology 2008; 8: 504 – 9.en_US
dc.identifier.citedreferenceDing X, Chen M, Huang S, et al. Nonsteroidal anti‐inflammatory drugs for prevention of post‐ERCP pancreatitis: a meta‐analysis. Gastrointest Endosc 2012; 76: 1152 – 9.en_US
dc.identifier.citedreferenceGu WJ, Wei CY, Yin RX. Antioxidant supplementation for the prevention of post‐endoscopic retrograde cholangiopancreatography pancreatitis: a meta‐analysis of randomized controlled trials. Nutr J 2013; 12: 23.en_US
dc.identifier.citedreferenceYuhara H, Ogawa M, Kawaguchi Y, et al. Pharmacologic prophylaxis of post‐endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta‐analysis. J Gastroenterol 2013 [Epub ahead of print].en_US
dc.identifier.citedreferenceHiggins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at: http://www.cochrane.org/training/cochrane-handbook. Accessed January 18, 2012.en_US
dc.identifier.citedreferenceAgency for Healthcare Research and Quality. Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0 (Draft posted October 2007). Rockville, MD. Available at: http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf. Accessed January 18, 2012.en_US
dc.identifier.citedreferenceHiggins JPT, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available at: http://www.cochrane.org/training/cochrane-handbook. Accessed January 18, 2012.en_US
dc.identifier.citedreferenceAdes AE, Welton N, Lu G. Mixed treatments comparisons. Available at: http://www.bris.ac.uk/social-community-medicine/projects/mpes/mtc. Accessed January 20, 2012.en_US
dc.identifier.citedreferenceNtzoufras I. Bayesian Modeling Using WinBUGS. Hoboken, NJ: John Wiley & Sons, 2009.en_US
dc.identifier.citedreferenceSalanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple‐treatment meta‐analysis: an overview and tutorial. J Clin Epidemiol 2011; 64: 163 – 71.en_US
dc.identifier.citedreferenceJaynes ET. Confidence Intervals vs Bayesian Intervals. In: Hooker Harper WL, Hooker CA, ed. Foundations of Probability Theory, Statistical Inference, and Statistical Theories of Science. Dordrecht: D. Reidel, 1976: 175 – 257.en_US
dc.identifier.citedreferenceWhite IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta‐analysis: model estimation using multivariate meta‐regression. Res Synthesis Methods 2012; 3: 111 – 25.en_US
dc.identifier.citedreferenceChatellier G, Zapletal E, Lemaitre D, et al. The number needed to treat: a clinically useful nomogram in its proper context. BMJ 1996; 312: 426 – 9.en_US
dc.identifier.citedreferenceAndriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post‐ERCP pancreatitis: a multicenter, placebo‐controlled, randomized clinical trial. Gastrointest Endosc 2002; 56: 488 – 95.en_US
dc.identifier.citedreferenceAndriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCP‐related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2: 713 – 8.en_US
dc.identifier.citedreferenceBudzynska A, Marek T, Nowak A, et al. A prospective, randomized, placebo‐controlled trial of prednisone and allopurinol in the prevention of ERCP‐induced pancreatitis. Endoscopy 2001; 33: 766 – 72.en_US
dc.identifier.citedreferenceChen XT, Fei ZY, Shen YF, et al. Clinical observation on ulinastatin for the prevention of post‐ERCP pancreatitis. Shandong Med J 2005; 45: 44 – 5.en_US
dc.identifier.citedreferenceGong P, Wang ZY, Tai PJ, et al. Prevention and treatment for post ERCP pancreatitis. J Hepatobiliary Surg 2004; 12: 101 – 3.en_US
dc.identifier.citedreferenceKwon YH, Kim JY, Lee SJ, et al. Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?. Korean J Gastroenterol 2012; 59: 232 – 8.en_US
dc.identifier.citedreferenceManolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post‐ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55: 470 – 5.en_US
dc.identifier.citedreferenceChen W, Chang Y, Yang J, et al. Clinical study of prophylactic effect of proton pump inhibitor combined with somatostatin and gabexate on post‐ERCP pancreatitis and hyperamylasemia. Chin J Gastroenterol 2009; 14: 414 – 7.en_US
dc.identifier.citedreferenceGorgul A, Kayhan B, Mentes BB, et al. The comparison of the effect of somatostatin and SMS 201‐995 on enzyme change following endoscopic retrograde cholangiopancreotography. Gazi Med J 1998; 9: 41165.en_US
dc.identifier.citedreferenceArvanitidis D, Anagnostopoulos GK, Giannopoulos D, et al. Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004; 19: 278 – 82.en_US
dc.identifier.citedreferenceChan HH, Lai KH, Lin CK, et al. Effect of somatostatin in the prevention of pancreatic complications after endoscopic retrograde cholangiopancreatography. J Chin Med Assoc 2008; 71: 605 – 9.en_US
dc.identifier.citedreferenceDeviere J, Le Moine O, Van Laethem JL, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120: 498 – 505.en_US
dc.identifier.citedreferenceFujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on post‐endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006; 21: 1065 – 9.en_US
dc.identifier.citedreferenceManes G, Ardizzone S, Lombardi G, et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post‐ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007; 65: 982 – 7.en_US
dc.identifier.citedreferencePark KT, Kang DH, Choi CW, et al. Is high‐dose nafamostat mesilate effective for the prevention of post‐ERCP pancreatitis, especially in high‐risk patients? Pancreas 2011; 40: 1215 – 9.en_US
dc.identifier.citedreferenceSherman S, Cheng CL, Costamagna G, et al. Efficacy of recombinant human interleukin‐10 in prevention of post‐endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009; 38: 267 – 74.en_US
dc.identifier.citedreferenceSong AL, Yin LN, Kou ZM. Preventive effects of ulinastatin on post ERCP hyperamylasemia and acute pancreatitis. J Lanzhou Univ (Med Sci) 2005; 31: 24 – 5.en_US
dc.identifier.citedreferenceRusso A, Virgilio C, Aprile G, et al. Effect of octreotide on pancreatic reactions following ERCP. Giornale Italiano di Endoscopia Digestiva 1992; 15: 139 – 45.en_US
dc.identifier.citedreferenceBaldazzi G, Conti C, Spotti EG, et al. Prevention of post‐ERCP acute pancreatitis with octreotide. Il Giornale di chirurgia 1994; 15: 359 – 62.en_US
dc.identifier.citedreferenceMontano Loza A, Garcia Correa J, Gonzalez Ojeda A, et al. Prevention of hyperamilasemia and pancreatitis after endoscopic retrograde cholangiopancreatography with rectal administration of indomethacin. Rev Gastroenterol Mex 2006; 71: 262 – 8.en_US
dc.identifier.citedreferenceMontano Loza A, Rodriguez Lomeli X, Garcia Correa JE, et al. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 2007; 99: 330 – 6.en_US
dc.identifier.citedreferenceWollschlager S, Patzold K, Bulang T, et al. Effect of preventive selenium administration on development of ERCP‐induced acute pancreatitis. Med Klin (Munich) 1999; 94 ( Suppl. 3 ): 81 – 3.en_US
dc.identifier.citedreferenceBorsch G, Bergbauer M, Nebel W, et al. Effect of somatostatin on amylase level and pancreatitis rate following ERCP. Die Medizinische Welt 1984; 35: 109 – 12.en_US
dc.identifier.citedreferenceDobronte Z, Toldy E, Mark L, et al. Effects of rectal indomethacin in the prevention of post‐ERCP acute pancreatitis. Orv Hetil 2012; 153: 990 – 6.en_US
dc.identifier.citedreferenceYasuda Y. Clinical effect of tripsin inhibitor (Urinastatin) for escape of pancreatic enzyme post ERCP. Jpn Pharmacol Ther 1987; 42: 77 – 82.en_US
dc.identifier.citedreferenceCotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383 – 93.en_US
dc.identifier.citedreferenceTestoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24‐h prophylaxis in patients at high risk for post‐ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15: 965 – 72.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt12534-sup-0002-AppendixS2.pdf
Size:
1.090MB
Format:
PDF
View/Open
Name:
apt12534-sup-0001-AppendixS1.pdf
Size:
137.7KB
Format:
PDF
View/Open
Name:
apt12534.pdf
Size:
430.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.